Who Gets Access to Emerging Mental Healthcare?

A Breakthrough for Whom?

Medical innovation tends to produce an understandable kind of excitement.

A treatment works differently.

A clinical trial produces encouraging results.

A previously difficult condition becomes more treatable.

Attention turns toward the breakthrough.

But eventually another question arrives:

Who can actually receive it?

The answer depends on considerably more than whether a medicine exists.

Can a patient afford treatment?

Does insurance cover it?

Is there a qualified provider nearby?

Can the patient take several hours away from work?

Can they arrange transportation?

Do they trust the healthcare system offering it?

Were people like them adequately represented in the research establishing its safety and effectiveness?

Does the treatment require specialized facilities that simply do not exist where they live?

These are not secondary questions.

They determine whether scientific progress becomes healthcare.

Ketamine Already Shows Us the Problem

Ketamine provides an unusually useful example because the treatment already exists while access remains uneven.

Racemic ketamine is FDA-approved as an anesthetic. Its psychiatric use, including IV treatment for depression, is off-label.

A 2025 review of psychiatric ketamine practice patterns identified financial barriers associated with limited insurance coverage and reduced availability in rural areas.

That creates an immediate divide.

A treatment can have a substantial research literature and still remain practically inaccessible to someone who cannot afford out-of-pocket treatment or does not live near a provider.

Scientific availability and practical availability are not the same thing.

Esketamine Solves One Problem—and Creates Others

Esketamine illustrates the complexity from another direction.

SPRAVATO, the esketamine nasal spray, has FDA-approved psychiatric indications and therefore operates through a different regulatory and reimbursement environment than off-label IV racemic ketamine.

But approval does not mean someone simply picks up the medication and uses it at home.

SPRAVATO is distributed through a Risk Evaluation and Mitigation Strategy, or REMS. It must be administered in certified healthcare settings, and patients must be monitored by healthcare professionals for at least two hours after administration.

Those requirements exist for safety.

But safety infrastructure has consequences.

A patient needs access to a certified treatment location.

The facility needs trained staff and appropriate space.

The patient needs time.

Transportation may be necessary.

Work and childcare may need to be rearranged.

The same infrastructure that makes treatment safer can make treatment harder to reach.

That doesn't mean the safeguards are unnecessary.

It means access has to be considered when we design the system around the medicine.

Geography Is Healthcare

Imagine two patients with similar clinical circumstances.

One lives fifteen minutes from a major medical center.

The other lives three hours from the nearest specialized treatment provider.

The medicine may be identical.

Their access to it is not.

This problem becomes particularly important for treatments requiring extended in-person administration or monitoring.

Researchers examining the future of psychedelic-assisted therapy in rural communities have identified geographic distance, economics, cultural factors and existing healthcare-provider shortages as potential barriers.

The problem isn't unique to psychedelics.

But psychedelic treatment models may amplify it.

If future therapies require preparation sessions, prolonged supervised drug administration and subsequent therapeutic or integration sessions, the healthcare system isn't merely delivering a medication.

It is delivering an experience-intensive clinical service.

That requires infrastructure.

And infrastructure has geography.

Who Was Actually Studied?

Access begins even earlier than clinical delivery.

It begins with research.

If the people participating in clinical trials don't adequately represent the population that will eventually receive a treatment, important questions remain.

A systematic review examining psychedelic studies found that among 1,393 participants, approximately 85% were non-Hispanic White. In U.S. studies, approximately 3.4% of participants were Black and 7.4% were Hispanic or Latino.

Another systematic review of psychedelic-assisted psychotherapy randomized trials similarly found significant underrepresentation of Black/African-American and Hispanic/Latino participants.

And a 2025 analysis of classic-psychedelic clinical trials found that White participants represented 87.2% of participants in the included psilocybin studies, compared with 3% Black participants.

Representation has improved in some areas.

The imbalance has not disappeared.

Why Representation Matters

Clinical-trial diversity is sometimes discussed as though it were primarily about demographics.

It is also about scientific confidence.

People differ in genetics, health conditions, medications, environmental exposures, cultural backgrounds and healthcare experiences.

Psychologically intensive treatments introduce additional variables.

The relationship between patient and clinician matters.

Expectations matter.

Cultural interpretations may matter.

The meaning assigned to an altered state may differ considerably among people from different religious, cultural or social backgrounds.

If research repeatedly studies a narrow population, researchers have less information about how well findings generalize beyond that population.

Underrepresentation therefore creates both an equity problem and a scientific one.

Why Don't More People Participate?

The easy explanation is that certain communities simply aren't interested.

The evidence suggests something considerably more complicated.

Research examining barriers to clinical-trial participation has identified differences between what research staff assume and what potential participants actually report.

In one mixed-method study, trial staff tended to emphasize logistics and reluctance to undergo additional treatment. Community members emphasized inadequate information and lack of trust in their healthcare teams. Both groups identified hesitancy toward research as important.

A 2025 qualitative study involving low-income Black Americans examining attitudes toward psychedelic-assisted therapy found a mixture of openness and hesitation. Participants raised concerns involving historical racism in healthcare, research, drug prescribing and criminalization, while emphasizing autonomy, trust, community engagement and practical barriers such as transportation and childcare.

Those concerns cannot be solved simply by changing the photograph on a recruitment advertisement.

Trust is relational.

It has to be earned.

Research With Communities, Not Simply About Them

One possible response is community-engaged research.

Rather than designing a study and then asking underrepresented communities to participate, community-engaged approaches involve relevant communities earlier in the research process.

That might include identifying local stakeholders.

Consulting community organizations.

Co-designing recruitment strategies.

Understanding cultural concerns.

Creating mechanisms for ongoing feedback.

Yet a systematic review published in the February 2026 issue of Neuroscience & Biobehavioral Reviews examined 27 U.S. studies of psilocybin, MDMA and LSD over the preceding decade and found community-engaged research practices in only three—about 11%. All three used community consultation, a relatively limited form of engagement. (Original systematic review)

Better representation may therefore require more than broader recruitment.

It may require reconsidering who participates in designing the research itself.

Access Is More Than Race

Race and ethnicity matter.

They are not the only dimensions of access.

A wealthy patient living near a major metropolitan medical center encounters a different healthcare system from a low-income patient in a rural community.

Language matters.

Disability matters.

Insurance matters.

Transportation matters.

Employment flexibility matters.

Childcare matters.

Digital access matters.

Provider availability matters.

Immigration circumstances may matter.

Culture and religious beliefs may influence whether someone trusts or even wants a particular treatment.

An access strategy focused on only one demographic characteristic can therefore miss the architecture producing the barrier.

The better question is:

What stands between this person and appropriate care?

The Cost of Time

Healthcare costs are usually discussed in dollars.

Time is also a cost.

A conventional prescription may require a brief appointment followed by medication taken at home.

Some emerging psychiatric treatments operate very differently.

A patient may need:

an evaluation,

preparation,

transportation,

hours in a clinical setting,

monitoring,

repeated visits,

and potentially psychotherapy or integration work.

For an hourly worker, every appointment may represent lost income.

For a parent, it may mean childcare.

For someone dependent on public transportation, it may require most of a day.

For a rural patient, it may require travel or lodging.

Two treatments with the same sticker price can therefore have radically different real-world costs.

Can We Make Treatment More Efficient Without Making It Less Safe?

This will become one of the defining questions for psychedelic medicine if more psychedelic drugs ultimately receive regulatory approval.

The obvious way to increase access is to reduce the resources required per patient.

But those resources may exist for a reason.

Researchers have examined group models as one possible approach. One analysis estimated substantial reductions in clinician time and cost when psychedelic-assisted therapy incorporated group rather than entirely individual treatment structures.

That does not establish group treatment as appropriate for every patient or every therapy.

But it illustrates the kind of question the field will increasingly face:

Which parts of the treatment model are clinically necessary, and which parts are simply inherited from the way early trials were designed?

The answer affects both safety and affordability.

The Oregon Experiment

Oregon offers an early glimpse of what regulated psychedelic access can look like outside conventional clinical trials.

During 2025, Oregon's regulated psilocybin system recorded 5,935 clients participating in 5,375 sessions.

But participation was not demographically representative.

White participants accounted for between 84.1% and 91.5% of clients across quarterly reporting. Hispanic/Latino participation was approximately 7.1%, while African American participation was approximately 2.1%.

Nearly one-third of participants lived outside Oregon.

Those numbers do not tell us why each individual did or did not participate.

But they demonstrate something important:

creating legal access does not automatically create equitable access.

The law can open the door.

Cost, geography, culture and infrastructure still determine who walks through it.

Access and Evidence Can Become a Feedback Loop

There is another problem.

Underrepresentation in research can reduce confidence that findings generalize broadly.

Limited trust can then reduce participation.

Limited participation produces less representative evidence.

And when treatments reach the real world, high cost or limited infrastructure can again concentrate access among particular populations.

Research and healthcare access can therefore reinforce one another.

Breaking that cycle may require thinking about equity before a therapy reaches the market rather than trying to repair access afterward.

The Danger of Calling Something a Revolution

Emerging mental-health treatments are frequently described as revolutionary.

Sometimes the science may justify genuine excitement.

But revolutions in medicine aren't measured only by what happens in laboratories or clinical trials.

They are eventually measured by what happens in healthcare systems.

Who can prescribe?

Who can administer?

Who pays?

Who is trained?

Where does treatment occur?

How much time does it require?

Who was included in the evidence base?

Who trusts the institutions providing it?

And who gets left out?

Those questions are less exciting than announcing a breakthrough.

They may determine whether the breakthrough matters.

What We Know

Ketamine and esketamine have created new treatment possibilities in psychiatry, particularly around treatment-resistant depression.

Access to off-label ketamine can be constrained by cost, insurance coverage and geography.

SPRAVATO requires certified treatment infrastructure and post-administration monitoring under its REMS program.

Racial and ethnic underrepresentation remains well documented in psychedelic clinical research.

Practical barriers such as transportation, childcare and time can interact with trust, culture and historical experiences with healthcare.

And early real-world psychedelic programs demonstrate that legal availability alone does not necessarily produce representative participation.

What We Don't Know

We don't yet know what future FDA-approved psychedelic treatment models will ultimately look like.

We don't know how insurers will approach every emerging therapy.

We don't know which components of intensive treatment models will prove essential and which might eventually be delivered more efficiently.

We don't yet have sufficiently representative research to answer every question about how psychedelic therapies perform across diverse populations.

And we don't know whether the healthcare system will solve these access problems before new therapies arrive—or after disparities have already become established.

The Question That Remains

Medicine understandably asks:

Does the treatment work?

It is the right first question.

But it cannot be the last.

A therapy can be pharmacologically innovative and financially inaccessible.

Clinically effective and geographically unavailable.

Scientifically promising and culturally mistrusted.

Legally permitted and practically unreachable.

None of those contradictions invalidate the medicine.

They reveal the system surrounding it.

Psychedelic medicine may eventually expand what psychiatry is capable of offering.

Ketamine and esketamine already provide an early view of both the possibilities and the logistical realities of delivering treatments that require more than writing a prescription.

The next breakthrough may therefore require innovation somewhere other than pharmacology.

Insurance.

Infrastructure.

Research design.

Training.

Community engagement.

Delivery models.

Trust.

Because discovering that a treatment works is only one part of creating healthcare.

The other is building a system through which appropriate patients can actually receive it.

And that leaves a question every medical breakthrough eventually has to answer:

A treatment people cannot reach may still be a breakthrough—but for whom?

Sources & Further Reading

Community engagement: Disengaged: A systematic review of community engagement in psychedelic-assisted therapy research, Neuroscience & Biobehavioral Reviews, February 2026. The authors reviewed 27 U.S. studies and identified community-engaged research in three (11.11%), all using community consultation. This finding concerns the included studies, not all psychedelic research worldwide.

Medical Note

This article is provided for informational and educational purposes only and does not constitute medical advice, diagnosis or treatment.

Eligibility for ketamine, esketamine or investigational psychedelic therapies requires individualized assessment by appropriately qualified healthcare professionals.